{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:49:04Z","timestamp":1777495744260,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.maturitas.2019.08.003","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T10:45:32Z","timestamp":1565433932000},"page":"12-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-4003","authenticated-orcid":false,"given":"Adrian V.","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-416X","authenticated-orcid":false,"given":"Faustino R.","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-2419","authenticated-orcid":false,"given":"Alejandro","family":"Piscoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Pasupuleti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuani M.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-9409","authenticated-orcid":false,"given":"Priyaleela","family":"Thota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2019.08.003_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice","volume":"374","author":"Black","year":"2016","journal-title":"Postmenopausal Osteoporosis. N Engl J Med"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.maturitas.2003.12.006","article-title":"Postmenopausal osteoporosis and alendronate","volume":"48","author":"P\u00e9rez-L\u00f3pez","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/joim.12873","article-title":"Treating osteoporosis to prevent fractures: current concepts and future developments","volume":"285","author":"Lorentzon","year":"2019","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0020","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","article-title":"Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement","volume":"101","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/14728214.2017.1362389","article-title":"Emerging anabolic agents in the treatment of osteoporosis","volume":"22","author":"Lovato","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2018.11.010","article-title":"New therapeutic targets for osteoporosis","volume":"120","author":"Anagnostis","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11739-018-1874-2","article-title":"Guidelines for the management of osteoporosis and fragility fractures","volume":"14","author":"Nuti","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0060","series-title":"Cochrane Methods. Cochrane Database of Systematic Reviews Issue 10","article-title":"A revised tool for assessing risk of bias in randomized trials","author":"Higgins","year":"2016"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-Comparison and network-meta-Analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0075","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ije\/dyn204","article-title":"Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified","volume":"37","author":"Higgins","year":"2008","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0080","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. Teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2008-1046787","article-title":"Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial","volume":"40","author":"Anastasilakis","year":"2008","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0090","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effect of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0100","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0105","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0120","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0125","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0135","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized linical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00774-008-0871-3","article-title":"Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study","volume":"26","author":"Miyauchi","year":"2008","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0145","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0150","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0155","first-page":"418","article-title":"Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience","volume":"56","author":"Sethi","year":"2008","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0160","first-page":"289","article-title":"Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study","volume":"86","author":"Khastgir","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/09513590312331290398","article-title":"Five-year changes in bone density, and their relationship to plasma estradiol and pretreatment bone density, in an older population of postmenopausal women using long-term estradiol implants","volume":"17","author":"Vashisht","year":"2003","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/13697137.2012.688079","article-title":"The evolution of selective estrogen receptor modulators in osteoporosis therapy","volume":"15","author":"Hadji","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0175","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0180","doi-asserted-by":"crossref","DOI":"10.1185\/03007995.2014.908279","article-title":"Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women","volume":"30","author":"Ellis","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0185","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.maturitas.2019.08.003_bib0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13018-018-0865-3","article-title":"Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis","volume":"13","author":"Wu","year":"2018","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0195","doi-asserted-by":"crossref","first-page":"e192416","DOI":"10.1001\/jamanetworkopen.2019.2416","article-title":"Comparison of risk of osteoporotic fracture in denosumab vs alendronate treatment within 3 years of initiation","volume":"2","author":"Pedersen","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ecl.2016.09.009","article-title":"Drug-related adverse events of osteoporosis therapy","volume":"46","author":"Khan","year":"2017","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00223-009-9323-x","article-title":"Gastric and esophagus events before and during treatment of osteoporosis","volume":"86","author":"Vestergaard","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","article-title":"Reports of esophageal cancer with oral bisphosphonate use","volume":"360","author":"Wysowski","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0215","doi-asserted-by":"crossref","DOI":"10.2165\/00002018-200629020-00005","article-title":"Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England","volume":"29","author":"Aurich-Barrera","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2019.04.003","article-title":"Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: large prospective cohort study in UK women","volume":"124","author":"Wotton","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0225","doi-asserted-by":"crossref","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review","author":"Fink","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ecl.2016.09.009","article-title":"Drug-related adverse events of osteoporosis therapy","volume":"46","author":"Khan","year":"2017","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0235","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1210\/jc.2018-02614","article-title":"Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention","volume":"104","author":"Mai","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0240","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/13697137.2018.1554645","article-title":"Factors related to muscle strength in postmenopausal women aged younger than 65 years with normal vitamin D status","volume":"22","author":"Garcia-Alfaro","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0245","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1519\/JSC.0000000000002089","article-title":"Effects of two training modalities on body fat and insulin resistance in postmenopausal women","volume":"31","author":"Henr\u00edquez","year":"2017","journal-title":"J. Strength Cond. Res."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0250","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/GME.0000000000000936","article-title":"Effect of programmed exercise on insulin sensitivity in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Bueno-Notivol","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0255","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13697137.2018.1561666","article-title":"Metabolic syndrome during female midlife: what are the risks?","volume":"22","author":"Chedraui","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00592-018-1101-7","article-title":"Insulin resistance and bone: a biological partnership","volume":"55","author":"Conte","year":"2018","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0265","doi-asserted-by":"crossref","first-page":"e0206424","DOI":"10.1371\/journal.pone.0206424","article-title":"Predictors of metabolic syndrome in community-dwelling older adults","volume":"13","author":"Van Ancum","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0270","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s00198-017-4151-8","article-title":"Osteosarcopenia: where bone, muscle, and fat collide","volume":"28","author":"Hirschfeld","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0275","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.12411","article-title":"Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis","author":"Yeung","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0280","doi-asserted-by":"crossref","first-page":"e0198318","DOI":"10.1371\/journal.pone.0198318","article-title":"Correction: muscle mass, BMI, and mortality among adults in the United States: a population-based cohort study","volume":"13","author":"Abramowitz","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0285","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1590\/0004-2730000003374","article-title":"Physical exercise and osteoporosis: effects of different types of exercises on bone and physical function of postmenopausal women","volume":"58","author":"Moreira","year":"2014","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0290","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13813455.2018.1437750","article-title":"High-intensity interval training improves inflammatory and adipokine profiles in postmenopausal women with metabolic syndrome","volume":"125","author":"Steckling","year":"2019","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0295","series-title":"Postmenopausal Diseases and Disorders","isbn-type":"print","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/978-3-030-13936-0_25","article-title":"Anabolic agents for the treatment of postmenopausal osteoporosis","author":"Minisola","year":"2019","ISBN":"https:\/\/id.crossref.org\/isbn\/9783030139353"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0300","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","article-title":"Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis","volume":"30","author":"Reginster","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0305","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin EndocrinolMetab"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0310","series-title":"Forsteo, INN-teriparatide - europa.eu","author":"European Medicines Agency","year":"2019"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0315","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00198-018-04819-1","article-title":"Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE","volume":"30","author":"Eastell","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0320","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0325","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement","volume":"319","author":"US Preventive Services Task Force","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2019.08.003_bib0330","first-page":"2640","article-title":"Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis","volume":"23","author":"Yang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.maturitas.2019.08.003_bib0335","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-snalysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512219305663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512219305663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:14:12Z","timestamp":1759914852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512219305663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":67,"alternative-id":["S0378512219305663"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2019.08.003","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2019.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}